Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | INMT | O95050 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 2/20 | 0.32 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11483414 | 0.83 | L3MBTL1 (0.39) | L3MBTL1HTT | |
| SCHEMBL5621142 | 0.77 | — | — | |
| SCHEMBL12566554 | 0.73 | GAA (0.48) | GAAL3MBTL1INMTPOLBSMN1; SMN2 | |
| SCHEMBL13208851 | 0.69 | TOP2A (0.36) | GAAL3MBTL1TOP2ATOP2BSMN1; SMN2 | |
| SCHEMBL7148826 | 0.68 | GAA (0.46) | GAAL3MBTL1INMTPOLBSMN1; SMN2 | |
| SCHEMBL1690671 | 0.68 | — | — | |
| SCHEMBL2547919 | 0.65 | — | — | |
| SCHEMBL1316047 | 0.65 | — | — | |
| SCHEMBL5981904 | 0.65 | — | — | |
| SCHEMBL2248553 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023542-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-01-24 | — | — | US | claimed |
| US-20060167001-A1 | Pyridazinone-derivatives as pde4 inhibitors | ALTANA PHARMA AG (DE) | 2006-07-27 | — | — | US | claimed |
| US-20060094723-A1 | Composition comprising a pde4 inhibitor and a pde5 inhibitor | NYCOMED GMBH (DE) | 2006-05-04 | — | — | US | claimed |
| EP-1587512-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA Pharma AG (DE) | 2005-10-26 | — | — | EP | claimed |
| US-6953853-B2 | Phospholipase inhbitors; antiinflammatory agents; respiratory system disorders | ALTANA PHARMA AG (DE) | 2005-10-11 | — | — | US | claimed |
| EP-1556369-A1 | PYRIDAZINONE-DERIVATIVES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-07-27 | — | — | EP | claimed |
| WO-2004062671-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA PHARMA AG (DE) | 2004-07-29 | — | — | WO | claimed |
| US-20040127707-A1 | PDE4/7 inhibitors useful in treatment of airway disorders, autoimmune system disorders, skin disorders, arthritis, nerve system disorders | ALTANA PHARMA AG (DE) | 2004-07-01 | — | — | US | claimed |
| US-20040067946-A1 | Phthalatyinone-piperidino-derivatives as pde4 inhibitors | TAKEDA GMBH (DE) | 2004-04-08 | — | — | US | claimed |
| WO-2004018451-A1 | PYRIDAZINONE-DERIVATIVES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | WO | claimed |
| EP-0582788-A1 | 7-(Substituted)-9- (substituted glycyl)-amido)-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1994-02-16 | — | — | EP | claimed |
| EP-0193858-B1 | NEW 1-OXA-1-DETHIA-CEPHALOSPORIN COMPOUNDS AND ANTIBACTERIAL AGENT COMPRISING THE SAME | MERCK & CO. INC. (US) | 1991-11-27 | — | — | EP | claimed |
| EP-0188781-B1 | 1-OXA-1-DETHIA-CEPHALOSPORIN COMPOUNDS AND ANTIBACTERIAL AGENT COMPRISING THE SAME | MERCK & CO. INC. (US) | 1990-10-24 | — | — | EP | claimed |
| EP-0114128-B1 | 3-AMINO-2-OXO-AZETIDINE DERIVATIVES CONTAINING IN POSITION 1 A NITROGEN HETEROCYCLIC RADICAL, PROCESS FOR THEIR PREPARATION, THEIR USE AS THERAPEUTICAL AGENTS AND INTERMEDIATES FOR THEIR PREPARATION | ROUSSEL-UCLAF (FR) | 1989-03-22 | — | — | EP | claimed |
| EP-0193858-A1 | New 1-oxa-1-dethia-cephalosporin compounds and antibacterial agent comprising the same | MERCK & CO. INC. (US) | 1986-09-10 | — | — | EP | claimed |
| EP-0188781-A1 | 1-Oxa-1-dethia-cephalosporin compounds and antibacterial agent comprising the same | MERCK & CO. INC. (US) | 1986-07-30 | — | — | EP | claimed |
| US-4587047-A | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines | E. R. SQUIBB & SONS, INC. (US) | 1986-05-06 | — | — | US | claimed |
| EP-0018001-B1 | CHROMOPHORIC CEPHALOSPORIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR UTILISATION, COMPOSITIONS CONTAINING THEM AND THEIR PREPARATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-05-25 | — | — | EP | claimed |
| US-4226864-A | BACTERICIDES, ANTIBIOTICS | SHIONOGI & CO., LTD. (JP) | 1980-10-07 | — | — | US | claimed |
| US-4112219-A | Acyl derivatives of antibiotic BM123γ | AMERICAN CYANAMID COMPANY (US) | 1978-09-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094723-A1 | Composition comprising a pde4 inhibitor and a pde5 inhibitor | PDE5A, PDE12, PDE4A | GAA 132/4885L3MBTL1 3795/4885INMT 1696/4885 |
| US-20040067946-A1 | Phthalatyinone-piperidino-derivatives as pde4 inhibitors | PDE4A, PDE4B, PDE5A | GAA 770/4885L3MBTL1 4529/4885INMT 1515/4885 |
| US-20040127707-A1 | PDE4/7 inhibitors useful in treatment of airway disorders, autoimmune system disorders, skin disorders, arthritis, nerve system disorders | PDE4A, PDE4B, PDE7B | GAA 1185/4885L3MBTL1 3961/4885INMT 2587/4885 |
| US-20060167001-A1 | Pyridazinone-derivatives as pde4 inhibitors | PDE4A, PDE3A, PDE4B | GAA 607/4885L3MBTL1 4523/4885INMT 2212/4885 |
| US-20130023542-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | GAA 2152/4885L3MBTL1 3001/4885INMT 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.